New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial…
Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a…
DAEJEON, South Korea, Dec. 20, 2024 /PRNewswire/ -- Antimicrobial resistance (AMR) is a growing global health crisis because of microbes,…
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…
Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec.…
Milestone demonstrates the growing customer adoption of the Company’s proprietary technologyLEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems,…
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from…
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing…
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the…
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne --…